INVESTING IN OUR STORY

OUR STORY IS THE FUTURE

Our treatments have the potential to fuel a new era of dermatology.

Cassiopea S.p.A. is listed on the Swiss stock exchange (ticker: SKIN) with the vision of building a leading, fully integrated dermatology company. Cassiopea, Inc., our United States subsidiary, was created with the mission to commercialize Cassiopea’s products in the United States.

SHARE INFORMATION

Italian Financial Transactions Tax
The Italian Law n. 228 (published in the Gazzetta Ufficiale No. 302 on December 29, 2012) stipulates that a financial transaction tax amounting to 0.22% of the transaction value is to be levied on all financial transactions for listed securities.

Article 1, comma 491, stipulates that this Financial Transaction Tax is not applicable on securities issued by corporations that have a market capitalization of less than EUR 500 million as calculated on the average market capitalization in the month of November preceding the transaction.

Issued shares
10’750’000 ordinary, registered shares of nominal EUR 1 each, fully dematerialized.

Additionally approved shares
Delegation to the board of the faculty to issue n. 3,000,000 ordinary, registered shares of nominal EUR 1 each, fully dematerialized, to be issued according to sections 2443 and 2441, 1° subsection, Italian Civil Code (resolution valid until 18 March 2024).

Delegation to the board of the faculty to issue 1,000,000 ordinary, registered shares of nominal EUR 1 each, fully dematerialized, to be issued with the exclusion of subscription rights according to section 2443 and 2441, 4° subsection Italian Civil Code,  (resolution valid until 5 April 2023).

Delegation to the board of the faculty to issue 900,000 ordinary, registered shares of nominal EUR 1 each, fully dematerialized, to be issued according to section 2443 Italian Civil Code to cover the company’s obligations out of its Stock Option Program (“SOP”) (resolution valid until 28 May 2025).

OWNERSHIP STRUCTURE

Cosmo Pharmaceuticals NV 46.56%
Cosmo Holding Sarl 7.53%
Herz/Logistable Group 4.69%
LLB Swiss Investment AG   3.82%

KEY FINANCIAL DATA

EUR1,000 2019 2018 2017 2016 2015 2014
Income statements
Revenues - - - - - -
Other income 686 916 3,820 5,883 - -
Cost of sale - - - - - -
R&D costs (7,875) (12,240) (13,061) (14,310) (7,597) (3,858)
SG&A costs (3,879) (1,890) (1,484) (2,026) (760) (61)
Operating result (11,068) (13,214) (10,725) (10,453) (8,357) (3,919)
Profit (loss) before taxes (11,700) (12,656) (13,656) (9,496) (6,451) (3,883)
Profit (loss) after taxes (11,700) (12,656) (13,656) (9,496) (6,451) (2,776)
Statement of financial position
Non-current assets 12,536 9,760 9,104 5,941 232 1,463
Cash and cash equivalents 696 4,609 17,598 33,656 48,113 840
Other current assets 2,829 2,171 1,767 2,328 1,491 1,520
Interest bearing loans 10,664 - - - - -
Other liabilities 1,670 2,028 2,115 2,776 2,655 197
Equity attributable to owners of the Company 3,727 14,512 26,354 39,149 47,181 3,626
Equity ratio (in %) 23% 88% 93% 93% 95% 95%
Shares
Weighted average number of shares 10,000,000 10,000,000 10,000,000 10,000,000 5,795,890 5,795,890
Earnings (loss) per share (in EUR) (1.170) (1.266) (1.366) (0.950) (1.113) (0.479)

FINANCIAL PUBLICATIONS & PRESENTATIONS

DATE TITLE DOCUMENT
September 14, 2020 Public Investor presentation H.C. Wainwright Annual Global Conference
July 29, 2020 Cassiopea Half Year Report 2020
July 29, 2020 Half Year 2020 Financial Results Presentation
July 29, 2020 Invitation HY 2020 results and pipeline update conference call
June 3, 2020 Notice on Invitation Conference Call
May 28, 2020 Q1 2020 Interim Report
April 29, 2020 Shareholders meeting convocation
March 19, 2020 Cassiopea Annual Report 2019
March 19, 2020 2019 Financial Results Presentation
March 19, 2020 Invitation FY 2019 results and 2020 outlook/pipeline update conference call
DATE TITLE DOCUMENT
November 13-20, 2019 Credit Suisse & Jefferies Presentation
July 19, 2019 2019 Half Year Report
July 18, 2019 2019 Half Year Presentation
February 8, 2019 2018 Annual Report
DATE TITLE DOCUMENT
July 18, 2018 2018 Half Year Report
February 28, 2018 2017 Annual Report
DATE TITLE DOCUMENT
July 27, 2017 2017 Half Year Report
February 24, 2017 2016 Annual Report
DATE TITLE DOCUMENT
February 24, 2016 2015 Annual Report
DATE TITLE DOCUMENT
September 24, 2015 2015 Half Year Report
DATE
September 14, 2020
TITLE
Annual Report 2018
DATE
July 29, 2020
TITLE
Annual Report 2018
DATE
July 29, 2020
TITLE
Annual Report 2018
DATE
July 29, 2020
TITLE
Annual Report 2018
DATE
June 3, 2020
TITLE
Annual Report 2018
DATE
May 28, 2020
TITLE
Annual Report 2018
DATE
April 29, 2020
TITLE
Annual Report 2018
DATE
March 19, 2020
TITLE
Annual Report 2018
DATE
March 19, 2020
TITLE
Annual Report 2018
DATE
March 19, 2020
TITLE
Annual Report 2018
DATE
November 13-20, 2019
TITLE
Annual Report 2018
DATE
July 19, 2019
TITLE
Annual Report 2018
DATE
July 18, 2019
TITLE
Annual Report 2018
DATE
February 8, 2019
TITLE
Annual Report 2018
DATE
July 18, 2018
TITLE
Annual Report 2018
DATE
February 28, 2018
TITLE
Annual Report 2018
DATE
July 27, 2017
TITLE
Annual Report 2018
DATE
February 24, 2017
TITLE
Annual Report 2018
DATE
February 24, 2016
TITLE
Annual Report 2018
DATE
September 24, 2015
TITLE
Annual Report 2018

FINANCIAL CALENDAR

DATE TITLE ADD TO CALENDAR
Jul 29 2020 Cassiopea Half Year Report
Sep 14 - Sep 15 2020 H.C. Wainwright Annual Global Investors Conference, New York
Sep 23 2020 Investora, Zurich
Nov 17 - Nov 19 2020 Jefferies Global Health Care Conference, London
Nov 18 - Nov 20 2020 Credit Suisse Small & Mid Cap Conference, Zurich

CORPORATE GOVERNANCE

DATE TITLE Document
03/13/2020 Cassiopea S.p.A. - Articles of Association / Statuto
04/15/2020 2020 General Assembly / Assemblea degli azionisti
04/15/2020 2020 Ordinary General Assembly / Assemblea ordinaria
04/15/2020 2020 Extraordinary General Assembly / Assemblea straordinaria
04/21/2020 2020 Ordinary General Assembly - Lists of candidates for the board of directors of Cassiopea S.p.A. / Elenco dei candidati al consiglio di amministrazione di Cassiopea S.p.A.
04/22/2020 2020 Ordinary General Assembly - Cosmo Pharmaceuticals NV Proposal

LATEST NEWS

August 27, 2020
chevron right icon

Cassiopea Receives FDA Approval for Winlevi® (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptor

July 29, 2020
chevron right icon

Cassiopea Announces Results for First Half of 2020

June 23, 2020
chevron right icon

Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.